ATS: American Thoracic Society International Conference

A symposium at the 2023 American Thoracic Society (ATS) International Conference featured research on predictors of chronic obstructive pulmonary disease (COPD) occurrence and disease progression.

Anna E. Mullins, PhD, assistant professor at the Icahn School of Medicine at Mount Sinai, discusses the necessity of awareness of how health issues can present in World Trade Center (WTC) responders.

Posters presented at the 2023 American Thoracic Society International Conference called for improvements in care for chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.

Gerard Criner, MD, FACP, FACCP, professor and founding chair, Thoracic Medicine and Surgery, at the Lewis Katz School of Medicine at Temple University, discusses a new trial that investigated how long treatment would last for patients with emphysema, and if any complications arose.

Quantifying social determinants of health and addressing the factors that allow disparities to persist will require standardized measurements and targeted interventions, said a panel of experts at the 2023 American Thoracic Society International Conference.

Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society (ATS) International Conference Committee, highlights the need for more specialized care and research for children with respiratory diseases, who don't have access to the same therapies and testing as adults.

Rupal Shah, MD, associate professor at the University of California San Francisco, talks about how the onset of the COVID-19 pandemic created an opportunity for patients who have undergone a lung transplant to undergo spirometry testing at home instead of at the the hospital.

In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung function, and improved quality of life compared with patients given a placebo.

This year’s American Thoracic Society (ATS) International Conference will spotlight not only the latest research in respiratory medicine, but also timely themes such as minority health equity, the effects of climate on health, and reducing gun violence through advocacy.

Horace DeLisser, MD, associate dean for diversity and inclusion in undergraduate medical education at the Perelman School of Medicine at the University of Pennsylvania and associate professor of medicine in the pulmonary, allergy, and critical care division, looks forward to the American Thoracic Society (ATS) international conference to reconnect with friends and colleagues and stay up to date on clinical knowledge and controversial topics.

Abstracts from the ATS 2021 International Conference addressed patient decision-making frameworks for seeking care for chronic obstructive pulmonary disease (COPD) and tactics used to assist hospitals in implementing readmission reduction plans.

Abstracts from the ATS 2021 International Conference provided some insight into tactics that could improve the effectiveness of pulmonary rehabilitation programs in patients with chronic obstructive pulmonary disease (COPD).

Posters presented at the ATS 2021 International Conference noted some ways clinical characteristics associated with patients with chronic obstructive pulmonary disease (COPD) differ based on different demographics and smoking status.

It is already known that dual-eligible older adults are at an increased risk for death in the year following a stay in the intensive care unit (ICU), but it previously wasn't known whether dual-eligible status is linked with functional decline after an ICU stay.

Patients with refractory or unexplained chronic cough are concerned about how they appear to others, and it takes them many years to get diagnosed, according to posters presented at the American Thoracic Society 2021 International Conference.

Stephanie Lovinsky-Desir, MD, MS, describes her research on the impact of environmental factors on respiratory health among children.

Farrah Kheradmand, MD, explains the effects of vaping duration on lung function.

Fernando Holguin, MD, describes the relationship between comorbid metabolic syndrome and pulmonary disease.

During the ATS 2021 International Conference, several studies shed new light on 2 asthma biologics.

The e-cigarette or vaping product use–associated lung injury epidemic helped jumpstart the regulation of flavored e-cigarettes, said Laura Crotty Alexander, MD, ATSF.

Michelle M Cloutier, MD, is professor emerita at UCONN Health in Farmington, Connecticut, and chair of the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee Expert Panel Working Group.

Joe Zein, MD, PhD, outlines how sex and age differences can impact asthma disease course.

Stephanie Lovinsky-Desir, MD, MS, discusses the importance of addressing social determinants of health (SDOH) to improve outcomes in pediatric respiratory health.

Genome-wide association studies are building the potential for precision medicine for children with respiratory diseases, but the progress also comes with challenges related to cost and issues with early screening, according to speakers at the ATS 2021 International Conference.

Anthony Fauci, MD, told attendees at the ATS 2021 International Conference that the real-world evidence of vaccines against SARS-CoV-2, the virus that causes COVID-19, is even better than expected.

A pediatric infectious disease expert reviewed some developments in the vaccine development pipeline, especially new efforts targeting infant health through maternal immunizations.

Farrah Kheradmand, MD, gives an overview of her research on the mechanisms of vaping-associated lung injuries.

Fernando Holguin, MD, explains the mechanisms that account for increased risk of pulmonary disease among individuals with metabolic syndrome.

It has been really tricky to identify and appropriately treat vaping-associated lung diseases in the time of COVID-19, said Laura Crotty Alexander, MD, ATSF.

A novel biologic for severe asthma reduced exacerbations by 56%, according to a study published Wednesday in The New England Journal of Medicine.